Literature DB >> 17957379

Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation.

Alexandros A Rouvas1, Thanos D Papakostas, Ioannis D Ladas, Ioannis Vergados.   

Abstract

BACKGROUND: To report a case of enlargement of the post photodynamic therapy treatment (PDT) spot in a patient with retinal angiomatous proliferation (RAP) that was treated with PDT combined with an intravitreal injection of bevacizumab.
METHODS: 74-year-old woman with RAP due to age-related macular degeneration was treated with one verteporfin PDT session, sequenced by a single intravitreal injection of bevacizumab (1.25 mg) after 30 minutes.
RESULTS: The patient's visual acuity (VA) at baseline was 20/200 and is now at the 10-month follow-up visit 20/400, while the RAP has disappeared according to the indocyanine angiography (ICG) findings. The post PDT hypofluorescent treatment spot has enlarged from 1,450 microm at the day of the treatment, to 5,360 microm at the 6-week visit. The patient is now at the 10-month follow-up visit and the hypofluorescence is still persisting.
CONCLUSION: The simultaneous combination of PDT with bevacizumab in patients with RAP may enhance the photochemical stress in normal choroid with prolonged and magnified hypofluorescence in ICG, due to ischemia in normal choriocapillaries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17957379     DOI: 10.1007/s00417-007-0669-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  13 in total

Review 1.  Inhibitors of ocular neovascularization: promises and potential problems.

Authors:  Peter van Wijngaarden; Douglas J Coster; Keryn A Williams
Journal:  JAMA       Date:  2005-03-23       Impact factor: 56.272

2.  Choroidal infarction following photodynamic therapy with verteporfin.

Authors:  Christina M Klais; Michael D Ober; K Bailey Freund; Leonard H Ginsburg; Alan Luckie; Martine Mauget-Faÿsse; Gabriel Coscas; Nicole E Gross; Lawrence A Yannuzzi
Journal:  Arch Ophthalmol       Date:  2005-08

3.  Photodynamic therapy with verteporfin for retinal angiomatous proliferation.

Authors:  Francesco Boscia; Maurizio Battaglia Parodi; Claudio Furino; Michele Reibaldi; Carlo Sborgia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-09       Impact factor: 3.117

4.  Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function.

Authors:  Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

5.  Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.

Authors:  I Kim; A M Ryan; R Rohan; S Amano; S Agular; J W Miller; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-08       Impact factor: 4.799

6.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

7.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Authors:  Jeffrey S Heier; David S Boyer; Thomas A Ciulla; Philip J Ferrone; J Michael Jumper; Ronald C Gentile; Debbi Kotlovker; Carol Y Chung; Robert Y Kim
Journal:  Arch Ophthalmol       Date:  2006-11

8.  Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment.

Authors:  Francesco Boscia; Claudio Furino; Luigi Sborgia; Michele Reibaldi; Carlo Sborgia
Journal:  Am J Ophthalmol       Date:  2004-12       Impact factor: 5.258

9.  Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin.

Authors:  Ursula M Schmidt-Erfurth; Stephan Michels
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

10.  Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.

Authors:  Ratimir Lazic; Nikica Gabric
Journal:  Ophthalmology       Date:  2007-06       Impact factor: 12.079

View more
  4 in total

1.  Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.

Authors:  Sandro Saviano; Pia Easter Leon; Alessandro Mangogna; Daniele Tognetto
Journal:  Digit J Ophthalmol       Date:  2016-06-30

2.  Therapeutic benefit of melatonin in refractory central serous chorioretinopathy.

Authors:  A L Gramajo; G E Marquez; V E Torres; C P Juárez; R E Rosenstein; J D Luna
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

3.  One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.

Authors:  Young Gun Park; Young-Jung Roh
Journal:  BMC Ophthalmol       Date:  2015-12-21       Impact factor: 2.209

4.  Analysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-Series.

Authors:  Pukhraj Rishi; Neha Raka; Ekta Rishi
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.